Scaling smarter: a case study in overcoming cell therapy manufacturing and regulatory hurdles

Advancing allogeneic cell therapies to the clinic often relies on close collaboration with a manufacturing partner to refine production processes and accelerate regulatory approval. In this article, James Adams (Chief Technical Officer, Tr1X Inc.) speaks with Abigail Pinchbeck (Editor, BioInsights) about overcoming the challenges of a highly specialized manufacturing process, offering key lessons in scalability and workflow design. He also discusses overcoming assay and manufacturing complexities, leveraging platform technologies for rapid advancement, and the critical role of collaboration, technical alignment, and long-term planning in achieving efficient and successful clinical progression. Later, James is joined by technical experts from Miltenyi Biotec and Miltenyi Bioindustry to answer questions from our readers.

Please enter your email to access content Read now